A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
about
Progress in treatment of ANCA-associated vasculitisImmunotherapy of systemic sclerosisRecent advances in anti-neutrophil cytoplasmic antibody-associated vasculitisSpotlight on rituximab in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis: current perspectivesUpdates in ANCA-associated vasculitisThe immunopathology of ANCA-associated vasculitisConditions in subjects with rheumatic diseases: pulmonary manifestations of vasculitidesThe effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease.B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.Efficacy and safety of rituximab as maintenance therapy for relapsing granulomatosis with polyangiitis—a case seriesLate-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.Management of ANCA-associated vasculitis: Current trends and future prospectsLate-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms.Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitisRheumatoid vasculitis: vanishing menace or target for new treatments?Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides.Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab in combination with corticosteroids for the treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis: a NICE single technology appraisalCurrent therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximabImproved prognosis in Norwegian patients with glomerulonephritis associated with anti-neutrophil cytoplasmic antibodies.Randomized trial of enteric-coated mycophenolate sodium versus mycophenolate mofetil in multi-system autoimmune disease.Rituximab for the treatment of Churg-Strauss syndrome with renal involvement.Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis.Rituximab in severe skin diseases: target, disease, and doseEfficacy of Rituximab in Refractory Inflammatory Myopathies Associated with Anti- Synthetase Auto-Antibodies: An Open-Label, Phase II TrialLow immunoglobulin levels increase the risk of severe hypogammaglobulinemia in granulomatosis with polyangiitis patients receiving rituximab.Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.Biologic agents in systemic vasculitis.B Cell in Autoimmune Diseases.Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis.Clinical outcomes of remission induction therapy for severe antineutrophil cytoplasmic antibody-associated vasculitis.Interferon-α induced remission in three patients with eosinophilic granulomatosis and polyangiitis. A case study.Experience with rituximab in the treatment of antineutrophil cytoplasmic antibody associated vasculitisRituximab versus azathioprine as therapy for maintenance of remission for anti-neutrophil cytoplasm antibody-associated vasculitis (RITAZAREM): study protocol for a randomized controlled trial.Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).Biologics in children's autoimmune disorders: efficacy and safety.Neurological manifestations of chronic graft-versus-host disease after allogeneic haematopoietic stem cell transplantation: report from the Consensus Conference on Clinical Practice in chronic graft-versus-host disease.Rituximab in induction therapy for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis.Recommendations for the use of rituximab in anti-neutrophil cytoplasm antibody-associated vasculitis.
P2860
Q21195258-8AA73B69-2CB8-4A37-AF19-5EAFB6E26422Q24634395-7692EB04-81E6-42DA-9AF6-E8D3096B9533Q26751357-2D487619-CC10-47A0-AC5B-EAEF4E64992BQ26776308-BE1A9C1C-1579-40E0-A4C2-955EBEFC4DB4Q28069897-17656ABB-DBAA-4A55-B0BD-EE9C70CC9373Q28391531-E22E2A0C-5275-40E5-910D-E97EB6B04C53Q28393792-B92D1638-FCF0-4C9E-93A2-A41674213618Q33683956-E8A520D0-8880-43BD-8874-05E59582F7C8Q33706447-32A977B1-6AEE-4738-BB53-E85AFA78A60DQ33757209-6090D5FD-E758-4B9E-904A-B867AB445240Q33895391-B9E60F29-7BBD-49F5-BA74-6EB252F24CC0Q33947599-650996CE-69FC-4A63-83E6-0D371F1D158EQ34072947-5D96591A-6C75-4564-9DE0-C018277F1A93Q34075484-15FDDE27-F1BB-43FF-A722-3D3B805EF23AQ34176634-440EB488-7AF9-4286-A1A2-DBE704D28821Q34282077-963B8645-0DAD-4399-B160-19AC445B1964Q34500502-64ECB048-59CB-4369-B5F7-A5F479803859Q34573847-AA74DB8F-CE6F-4C70-A4CC-71B8352489B8Q35065425-4ECE7B56-E6F4-4F7D-9BC1-9C8A76C14136Q35212086-BCE0EA86-32C7-42F8-9DCC-F99CB92E6378Q35310520-DA8DDA7E-992C-4B20-A3D8-6B1F082C8841Q35557092-E76D9DCE-54C9-487C-9DA5-9D0E8F8A4FC3Q35557832-59A7F21B-8FDC-4C74-A7D3-6AEF9D4AAAB7Q35662018-2D6FFA10-CE68-4F41-9D27-431BF9A5C42CQ35683952-AE896AC7-4AAF-4C81-9F46-D94E8B23D2C9Q35833312-49B8238D-1F6E-4599-A0AD-CB5FE166A39BQ35887318-7AB17011-B785-482C-97DC-A598F45A6FC8Q35890027-880449E6-F3E3-4CA1-AB67-B8C8AAC870EBQ36934322-D8ED531C-A76D-402D-B8E2-5A5BCC97C9B1Q36954468-BA602248-F4D8-4B22-9AEC-E76D76B7B837Q37031689-EC482F8A-D88A-4518-81FE-6C8B0AB20848Q37106198-F88A45F1-4E26-485A-BE95-955BAA43EFE5Q37576518-65B45F04-5DD5-404B-85E8-53A4C0887F82Q37640836-6771F365-D689-41DD-A782-A649B128D390Q37686029-C49043E1-5D29-4268-B19D-DAB3E2A1BEC7Q37690935-C8E2ADD8-8CF1-4509-840A-A74BECDBC98CQ37765830-168CD9A6-69B1-4CEF-BCE5-0DDA4B3D47ABQ37789530-DE94F88B-C458-4B24-8562-C5EC2F90BCA1Q37859111-35420504-D5C8-4251-91DF-4AC04685F66BQ37879814-B84DA30B-DA00-4275-B373-E1ABE1806188
P2860
A multicenter survey of rituximab therapy for refractory antineutrophil cytoplasmic antibody-associated vasculitis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@ast
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@en
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@nl
type
label
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@ast
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@en
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@nl
prefLabel
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@ast
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@en
A multicenter survey of rituxi ...... ntibody-associated vasculitis.
@nl
P2093
P356
P1476
A multicenter survey of rituxi ...... antibody-associated vasculitis
@en
P2093
Afzal N Chaudhry
Alan D Salama
Alastair J Ferraro
Caroline O S Savage
David R W Jayne
Paul Brogan
P304
P356
10.1002/ART.24637
P577
2009-07-01T00:00:00Z